Kymera Therapeutics (KYMR) Common Equity (2019 - 2026)
Kymera Therapeutics (KYMR) posted quarterly Common Equity of $1.5 billion for Q1 2026, up 95.82% year-over-year from $786.2 million in Q1 2025, and down 2.53% quarter-over-quarter from $1.6 billion in Q4 2025.
Kymera Therapeutics (KYMR) Common Equity (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has reported Common Equity for 8 consecutive years, with $1.5 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity rose 95.82% year-over-year to $1.5 billion; the TTM figure through Mar 2026 stood at $1.5 billion (up 95.82% YoY), while the FY2025 annual figure was $1.6 billion, up 89.04% from the prior year.
- Common Equity eased to $1.5 billion in Q1 2026 per KYMR's latest filing, from $1.6 billion in the prior quarter.
- Across five years, Common Equity topped out at $1.6 billion in Q4 2025 and bottomed at $395.0 million in Q4 2023.
- Historically, Common Equity has averaged $733.3 million across 5 years, with a median of $684.9 million in 2024.
- Annual changes were most pronounced in 2023 — Common Equity fell 22.88% — and 2024, when it surged 125.75%.
- Kymera Therapeutics' Common Equity stood at $490.2 million in 2022, then declined by 19.42% to $395.0 million in 2023, then soared by 111.56% to $835.6 million in 2024, then surged by 89.04% to $1.6 billion in 2025, then decreased by 2.53% to $1.5 billion in 2026.
- Business Quant data shows KYMR's Common Equity at $1.5 billion in Q1 2026, $1.6 billion in Q4 2025, and $946.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Kymera Therapeutics | 9.72 Bn | 9.03 Bn | - | 1.51 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.51 Bn |
| Mar 31, 2026 | 1.54 Bn |
| Dec 31, 2025 | 1.58 Bn |
| Sep 30, 2025 | 946.26 Mn |
| Jun 30, 2025 | 971.48 Mn |
| Mar 31, 2025 | 786.23 Mn |
| Dec 31, 2024 | 835.62 Mn |
| Sep 30, 2024 | 892.93 Mn |
| Jun 30, 2024 | 684.92 Mn |
| Mar 31, 2024 | 711.20 Mn |
| Dec 31, 2023 | 394.97 Mn |
| Sep 30, 2023 | 395.54 Mn |
| Jun 30, 2023 | 435.43 Mn |
| Mar 31, 2023 | 462.01 Mn |
| Dec 31, 2022 | 490.15 Mn |
| Sep 30, 2022 | 512.89 Mn |
| Jun 30, 2022 | 397.95 Mn |
| Mar 31, 2022 | 428.72 Mn |
| Dec 31, 2021 | 459.64 Mn |
| Sep 30, 2021 | 483.14 Mn |